Söndag 22 December | 07:14:57 Europe / Stockholm

Prenumeration

2023-03-01 10:40:00

Redeye comments on the progress of the phase I trial of Lipisense and the 2023 rights issue, which renders a new Base Case.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/